Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PsyBio Therapeutics Corp PSYBF


Primary Symbol: V.PSYB.H

Healthcare Biotechnology
PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged... see more

Recent & Breaking News (TSXV:PSYB.H)

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire December 7, 2023

Canadian Investment Regulatory Organization Trading Halt - PSYB

Canada NewsWire December 6, 2023

Canadian Investment Regulatory Organization Trading Halt - PSYB

Canada NewsWire November 27, 2023

PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale

Newsfile July 21, 2023

PsyBio Announces Closing of Third Tranche of Private Placement

Newsfile April 20, 2023

PsyBio (TSXV:PSYB) CEO to speak to nextgen psychedelics

Brieanna McCutcheon  April 6, 2023

PsyBio Announces Panel Participation on NextGen Psychedelics at Benzinga Cannabis Capital Conference

Newsfile April 6, 2023

PsyBio Therapeutics Founder Wins Best Pitch at Investment Summit

Newsfile March 13, 2023

PsyBio (TSXV:PSYB) closes second tranche of private placement

John Ballem  January 16, 2023

PsyBio Announces Closing of Second Tranche of Private Placement

Newsfile January 13, 2023

PsyBio (TSXV:PSYB) appoints Ian Wisenberg to Board of Directors

Brieanna McCutcheon  January 10, 2023

PsyBio Announces Appointment of Ian Wisenberg to Board of Directors

Newsfile January 10, 2023

PsyBio (TSXV:PSYB) closes first tranche of private placement

Azuka Onwuka January 5, 2023

PsyBio Announces Closing of First Tranche of Private Placement Led by the Chairman and Chief Executive Officer with Participation from the Entire Board of Directors and Management Team and Provides Corporate Update

Newsfile January 5, 2023

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMT

Canada NewsWire December 8, 2022

PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio

Canada NewsWire December 6, 2022

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

Canada NewsWire December 1, 2022

PsyBio Therapeutics Reports Third Quarter 2022 Financial Results

Canada NewsWire November 29, 2022

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

Canada NewsWire October 11, 2022

PsyBio (TSXV:PSYB) recieves patent approval

Caroline Egan  September 19, 2022